Quest Diagnostics (DGX) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $194.19 -0.42%
EPS Growth %: +7.6%
Financial Fact:
Selling, general and administrative: 409M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +7.6%
Financial Fact:
Selling, general and administrative: 409M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.35, $0.02 better than the analyst estimate of $2.33. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Quest Diagnostics sees FY2024 EPS of $8.80-$9.00, versus the consensus of $8.86.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Chinese carmakers exploring Canada’s EV import quota, Joly says
- FDA launches Operation TrialBlazer to accelerate drug research
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
